Combination Antibody Market by 2024
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Global <strong>Market</strong> Study on <strong>Combination</strong> <strong>Antibody</strong><br />
Therapy: <strong>Antibody</strong>/<strong>Antibody</strong> <strong>Combination</strong><br />
Segment Expected to Dominate the Global <strong>Market</strong><br />
Through <strong>2024</strong>
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
Report Media Releases<br />
<strong>Combination</strong> <strong>Antibody</strong> <strong>Market</strong> in APAC Region Set to Witness<br />
Robust Growth through <strong>2024</strong><br />
Higher success ratio in treating and preventing cancer cells using combination antibody therapy<br />
is fuelling the demand for combination antibody drugs in the market. A study conducted <strong>by</strong><br />
Persistence <strong>Market</strong> Research (PMR) shows that the global market for combination antibody<br />
therapy is set to ride on a value CAGR of over 14% during the period of assessment to reach<br />
US$ 144,734.5 Million <strong>by</strong> <strong>2024</strong> end. In 2016, the global market was valued at over US$ 49,994<br />
Million characterizing the overwhelming popularity of antibody/antibody drugs amongst both<br />
practitioners and patients observed in recent years.<br />
<strong>Combination</strong> antibody therapy is receiving higher recognition from the oncological branch of<br />
medical science research. This is primarily due to the growing use of combination therapy over<br />
single drug treatments such as radiation or chemotherapy. In addition, companies that<br />
manufacture combination antibody drugs are actively focusing on developing superior drugs that<br />
will deliver standout results. Factors such as encouraging government policies, growing<br />
concerns over higher cancer prevalence worldwide, and increasing research and development<br />
activities coupled with heavier investments are expected to boost the overall market growth in<br />
the near future. Likewise, healthy R&D pipelines are leading towards higher product offerings<br />
and also propelling the growth of global combination antibody therapy market to a<br />
significant extent.<br />
A Sample of this Report is Available Upon Request @<br />
http://www.persistencemarketresearch.com/samples/11740<br />
Bottlenecks<br />
The prolonged attrition rate in product development cycle and arbitrary and stringent drug<br />
approval procedures are the major downsides of the market that are likely to inhibit the market<br />
growth during the forecast period. Moreover, lack of awareness on understanding the difference<br />
between immunotherapies and chemotherapies amongst healthcare professionals, which is<br />
restricting the optimal use of immunotherapies alongside conventional treatment modalities is an<br />
additional factor impeding the market growth. Further, late diagnosis or ignorance of any<br />
carcinogenic disorders may inevitably lead to higher cost of treatment.<br />
<strong>Market</strong> Forecast<br />
Based on combinations, antibody/antibody is projected to be the predominant segment of the<br />
market over the forecast period. In terms of revenue, the segment is expected to witness a<br />
healthy CAGR of over 17% between 2016 and <strong>2024</strong>. The growth is attributed to the increasing<br />
preference of antibody/antibody drugs as they have a lower risk of side effects for various cancer<br />
therapies. Whereas, the chemotherapy/antibody segment will hold the second position,<br />
accounting for 38.3% share of the market in 2016.<br />
<strong>Combination</strong> <strong>Antibody</strong> Therapy <strong>Market</strong> <strong>2024</strong>
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
Demand for combination antibody therapy will be high for breast cancer and lung cancer<br />
treatment on the basis of applications. The lung cancer segment is anticipated to expand at a<br />
value CAGR of 17.1% during the assessment period.<br />
By end user, hospitals are expected to be the largest segment of the market throughout the<br />
forecast period. In 2015, the segment was valued at US$ 26,906.5 Million, which is expected to<br />
surpass US$ 95,885 Million <strong>by</strong> <strong>2024</strong> end, reflecting a CAGR of 15.2%.<br />
From a regional perspective, North America will continue to be the leading market for<br />
combination antibody therapy over the forecast period. In addition, the region is set to witness a<br />
CAGR of over 13% in terms of value. Whereas, APAC is expected to reflect the fastest growth of<br />
the market during the forecast period in terms of value. Further, the market in the region is<br />
estimated to witness a 3.4X growth in terms of sales over <strong>2024</strong> owing to increasing prevalence<br />
of carcinogenic disorders in APAC.<br />
Request to View Tables of Content @ http://www.persistencemarketresearch.com/marketresearch/combination-antibody-therapy-market/toc<br />
Key participants functioning in the global market for combination antibody therapy include Roche<br />
Holdings AG, Amgen Incorporated, Novartis AG, Celgene Corporation, Biogen Inc., Seattle<br />
Genetics Inc., Genmab A/S, Bristol-Myers Squibb Company, Eli-Lilliy and Company and Sanofi.<br />
To Buy Full Report for a Single User @<br />
http://www.persistencemarketresearch.com/checkout/11740<br />
About Us:<br />
<strong>Combination</strong> <strong>Antibody</strong> Therapy <strong>Market</strong> <strong>2024</strong>
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
Persistence <strong>Market</strong> Research (PMR) is a third-platform research firm. Our research model is a<br />
unique collaboration of data analytics and market research methodology to help businesses<br />
achieve optimal performance.<br />
To support companies in overcoming complex business challenges, we follow a multi-disciplinary<br />
approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying<br />
real-time data collection, big data, and customer experience analytics, we deliver business<br />
intelligence for organizations of all sizes.<br />
Our offerings include pre-built reports that address every major sale, customized solutions to<br />
cater to client-specific needs, and consulting services to offer more value addition. Our nextgeneration<br />
research approach for exploring emerging technologies has allowed us to solve the<br />
most complex problems of clients. We do not follow a reactive approach, but a pro-active one.<br />
Expert analysts at PMR keep a tab on next-generation technologies in their R&D phase and<br />
provide the latest insights into these technologies when they are being commercialized. Our<br />
ground-breaking approach allows us to deliver market solutions before the technologies reach<br />
the market.<br />
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing<br />
startups. PMR’s collaborative environment is committed to building industry-specific solutions <strong>by</strong><br />
transforming data from multiple streams into a strategic asset.<br />
Contact Us:<br />
Persistence <strong>Market</strong> Research<br />
90 Sate Street, Suite 700 Albany, NY 12207<br />
Tel: +1-518-618-1030<br />
Email: sales@persistencemarketresearch.com<br />
Website: http://www.persistencemarketresearch.com/<br />
media@persistencemarketresearch.com<br />
Stay updated with our official Blog: http://pmrblog.com<br />
<strong>Combination</strong> <strong>Antibody</strong> Therapy <strong>Market</strong> <strong>2024</strong>
Change language